Friday, August 4, 2017

Molecular Templates Gets Investment From Takeda In Research, Licensing Deal

Austin-based Molecular Templates, a startup focused on the discovery, development and commercialization of next-generation immunotoxins for destroying cancer cells, and pharmaceuticals giant ,a href="http://www.takeda.com">Takeda Pharmaceuticals said on Thursday that they are in a new, research and licensing collaboration. According to the two, the collaboration will apply Molecular Templates' technology platform to potential therapeutic targets provided by Takeda. As part of the licensing deal, Takeda said it will make an equity investment in Molecular Templates, and will also provide upfront payments, development and commercial milestone payments, plus royalties on sales of commercial products developed through the collaboration. Financial details of that investment were not announced. Takeda will appoint a Director to the company's board as a result of the investment deal. Molecular Templates is led by Eric Poma, Ph.D., who serves both as CEo and Chief Scientific Officer of the company. More information »